Image: Evotec
The German pharmaceutical drug researcher Evotec has to look for a new boss. The CEO Werner Lanthaler, who comes from Eggelsberg in the Braunau district, is resigning for personal reasons before his contract expires after almost 15 years, the MDax-listed company surprisingly announced on Wednesday evening in Hamburg. The supervisory board has agreed to the resignation and is looking for a permanent successor within and outside of the company.
For the time being, supervisory board member Mario Polywka is expected to manage the company. This one had Evotec used to run the day-to-day business.
Lanthaler justified his resignation with one “extremely challenging and both physically and overall exhausting year 2023”. He could join the company in the next few years “not serving in the best possible way”. Supervisory Board Chairman Iris Löw-Friedrich thanked the manager “for his unique vision and the many important achievements over the past almost 15 years”. Lanthaler’s contract would actually have run until March 2026.
more from economics
